Meta-analysis of the prognostic value of circulating tumor cells detected with the CellSearch System in colorectal cancer
- PMID: 25880692
- PMCID: PMC4389311
- DOI: 10.1186/s12885-015-1218-9
Meta-analysis of the prognostic value of circulating tumor cells detected with the CellSearch System in colorectal cancer
Abstract
Background: The prognostic value of circulating tumor cells (CTCs) detected with the CellSearch System in patients with colorectal cancer (CRC) is controversial. The aim of our meta-analysis was to evaluate whether the detection of CTCs in the peripheral blood with the standardized CellSearch System has prognostic utility for patients with CRC.
Methods: The PubMed, Science Citation Index, Cochrane Database, Embase, and the references in relevant studies were systematically searched (up to December, 2014). No search restrictions were imposed. Our meta-analysis was performed in Stata software, version 12.0 (2011) (Stata Corp, College Station, TX, USA), with the odds ratio (OR), risk ratio (RR), hazard ratio (HR), and 95% confidence interval (95% CI) as the effect measures. Subgroup and sensitivity analyses were also conducted.
Results: Eleven studies containing 1847 patients with CRC were analyzed. There was a significantly higher incidence of CTCs in the metastasis-positive group than in the metastasis-negative group (OR = 4.06, 95% CI [1.74, 9.50], P < 0.01, I(2) = 0%). For hepatic metastasis, a type of metastasis, a higher incidence of CTCs was observed in the hepatic-metastasis-positive group than in the -negative group (OR = 2.61, 95% CI [1.73, 3.96], P < 0.01, I(2) = 0%). The presence of CTCs was significantly related to overall survival (HR = 2.00, 95% CI [1.49, 2.69], P < 0.01, I(2) = 67.1%) and progression-free survival (HR = 1.80, 95% CI [1.52, 2.13], P < 0.01, I(2) = 43.9%) of patients with CRC, regardless of the sampling time. The response rate for the CTC(+) groups was significantly lower than that for the CTC(-) groups at baseline and during treatment (baseline: 33% versus 39%, RR = 0.79, 95% CI [0.63, 0.99], P = 0.04, I(2) = 7.0%; during treatment: 17% versus 46%, RR = 0.41, 95% CI [0.22, 0.77], P = 0.01, I(2) = 0.0%;).
Conclusions: Our meta-analysis indicates that the detection of CTCs in the peripheral blood with the CellSearch System has prognostic utility for patients with CRC.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4389311/bin/12885_2015_1218_Fig1_HTML.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4389311/bin/12885_2015_1218_Fig2_HTML.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4389311/bin/12885_2015_1218_Fig3_HTML.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4389311/bin/12885_2015_1218_Fig4_HTML.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4389311/bin/12885_2015_1218_Fig5_HTML.gif)
Similar articles
-
Prognostic value of circulating tumor cells detected with the CellSearch System in patients with gastric cancer: evidence from a meta-analysis.Onco Targets Ther. 2018 Feb 26;11:1013-1023. doi: 10.2147/OTT.S154114. eCollection 2018. Onco Targets Ther. 2018. PMID: 29520152 Free PMC article.
-
The significant prognostic value of circulating tumor cells in colorectal cancer: A systematic review and meta-analysis.Curr Probl Cancer. 2018 Jan-Feb;42(1):95-106. doi: 10.1016/j.currproblcancer.2017.11.002. Epub 2017 Nov 29. Curr Probl Cancer. 2018. PMID: 29277243
-
Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review.BMC Cancer. 2017 Nov 7;17(1):725. doi: 10.1186/s12885-017-3704-8. BMC Cancer. 2017. PMID: 29115932 Free PMC article. Review.
-
Circulating tumor cells predict survival benefit from chemotherapy in patients with lung cancer.Oncotarget. 2016 Oct 11;7(41):67586-67596. doi: 10.18632/oncotarget.11707. Oncotarget. 2016. PMID: 27588489 Free PMC article. Review.
-
Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis.BMC Cancer. 2014 Dec 18;14:976. doi: 10.1186/1471-2407-14-976. BMC Cancer. 2014. PMID: 25519477 Free PMC article.
Cited by
-
Circulating Tumor Cells: How Far Have We Come with Mining These Seeds of Metastasis?Cancers (Basel). 2024 Feb 17;16(4):816. doi: 10.3390/cancers16040816. Cancers (Basel). 2024. PMID: 38398206 Free PMC article. Review.
-
Early Detection of Disease Progression in Metastatic Cancers: Could CTCs Improve RECIST Criteria?Biomedicines. 2024 Feb 7;12(2):388. doi: 10.3390/biomedicines12020388. Biomedicines. 2024. PMID: 38397990 Free PMC article.
-
Application of microfluidic technology based on surface-enhanced Raman scattering in cancer biomarker detection: A review.J Pharm Anal. 2023 Dec;13(12):1429-1451. doi: 10.1016/j.jpha.2023.08.009. Epub 2023 Aug 23. J Pharm Anal. 2023. PMID: 38223444 Free PMC article. Review.
-
Predictive value of circulating tumor cell counts during the treatment of cancer: interactions with the blood microenvironment.Int J Clin Oncol. 2023 Aug;28(8):1011-1022. doi: 10.1007/s10147-023-02355-5. Epub 2023 May 27. Int J Clin Oncol. 2023. PMID: 37243775
-
Prognostic Role of Circulating Tumor Cell Trajectories in Metastatic Colorectal Cancer.Cells. 2023 Apr 16;12(8):1172. doi: 10.3390/cells12081172. Cells. 2023. PMID: 37190081 Free PMC article.
References
-
- Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007;370(9582):143–52. doi: 10.1016/S0140-6736(07)61087-3. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical